 REHOVOT, Israel and WILMINGTON, Del., Jan. 28, 2021 GLOBE NEWSWIRE -- Ayala Pharmaceuticals, Inc. NASDAQ: AYLA, a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the first patient dosed in the Phase 2 TENACITY clinical trial of its potent, selective small molecule AL101, for the treatment of patients with Notch-activated recurrent or metastatic RM triple negative breast cancer TNBC. 